Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Luo Y et al. - The results show that ABT-751 is a tubulin-binding agent with antivascular properties. Microtubule disruption and morphological changes in vascular endothelial cells may be responsible, at least in part, for the dysfunction of tumor blood vessels after ABT-751 treatment.

Related Articles

Triple-negative breast cancer—current status and future directions
Annals of Oncology, 11/16/09    Relevance Score: 45%

Use of remifentanil as a sedative agent in critically ill adult patients: a meta-analysis
Anaesthesia, 11/11/09    Relevance Score: 45%

Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond
Heart Failure Reviews, 11/03/09    Relevance Score: 45%

The Impact of Bittering Agents on Pediatric Ingestions of Antifreeze
Clinical Pediatrics, 10/26/09    Relevance Score: 45%

The role of urate and xanthine oxidase in vascular oxidative stress: future directions
Therapeutics and Clinical Risk Management, 10/07/09    Relevance Score: 45%

Today in Basic Science/Genetics...keeping you current

Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity
Proceedings of the National Academy of Sciences of the United States of America, 12/09/09

A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy
Breast Cancer Research and Treatment, 12/09/09

Expression of Hiwi in human esophageal squamous cell carcinoma is significantly associated with poorer prognosis
BMC Cancer, 12/09/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address